U
NXTM

UBS’s NxStage Medical Inc. NXTM Stock Holding History

UBS’s Portfolio NXTM Stock Details NXTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		$192K Buy
14,568
+434
+3% +$5.84K ﹤0.01% 5221
2014
Q2 		$203K Sell
14,134
-741
-5% -$9.67K ﹤0.01% 5137
2014
Q1 		$190K Sell
14,875
-6,087
-29% -$79.4K ﹤0.01% 5250
2013
Q4 		$210K Buy
20,962
+1,865
+10% +$21.2K ﹤0.01% 5252
2013
Q3 		$251K Sell
19,097
-25,052
-57% -$329K ﹤0.01% 4901
2013
Q2 		$630K Buy
+44,149
New +$555K ﹤0.01% 3848

Other funds holding NXTM

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CAM
Cortina Asset Management Milwaukee, Wisconsin $1.62B AUM 15.44% 1-Year Est. Return
RIM
RS Investment Management San Francisco, California $9.73B AUM 3.24% 1-Year Est. Return
BA
Broadview Advisors Milwaukee, Wisconsin $324M AUM 0.76% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

UBS's NXTM Position: Q3 2014 in Review

UBS increased its NxStage Medical Inc. (NXTM) stake by 3.1% in Q3 2014, buying an estimated $5.84K and bringing the position to 14,568 shares worth $192K. The position accounts for ﹤0.01% of the portfolio, ranked #5221.

UBS first reported a position in NXTM in Q2 2013 and has held it in 6 quarters since. The position peaked at $630K in Q2 2013. 111 funds tracked by Wall St. Rank hold NXTM as of Q3 2014.

  • UBS held 14,568 shares of NxStage Medical Inc. worth $192K as of Q3 2014.
  • UBS bought 434 NxStage Medical Inc. shares in Q3 2014, an estimated $5.84K.
  • NxStage Medical Inc. made up ﹤0.01% of UBS's portfolio in Q3 2014, its #5221 holding.
  • UBS first reported a position in NxStage Medical Inc. in Q2 2013 and has held it in 6 quarters since.
  • UBS's NxStage Medical Inc. position peaked at $630K in Q2 2013.
  • 111 funds tracked by Wall St. Rank held NxStage Medical Inc. as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.